ERBB2 and breast cancer: Pertuzumab plus trastuzumab for the treatment of adjuvant HER2+ breast cancer was not recommended for reimbursement by the Pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) and was subsequently not publicly funded in Ontario [4].